Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly states that it remains committed to expanding industry collaboration to improve access to Zepbound. While we acknowledge the potential of CI to grow, our conviction lies in the belief ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing. The drug, administered via intravenous ...

Shareholders of Eli Lilly (Symbol: LLY) looking to boost their income beyond the stock's 0.8% annualized dividend yield can sell the June 2027 covered call at the $1000 strike and collect the ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest challenger. Over the past six months, Eli Lilly has ...

Two former Eli Lilly executives and their families will donate $20 million to IU Health Foundation — the largest philanthropic gift in the foundation's history — to establish the Institute for ...

Novo Nordisk would not comment on the new pharmacy benefits arrangements. But a spokesperson for Eli Lilly told CNBC, "Lilly will continue to work with those in health care, government and the ...